Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Stage IVC Major Salivary Gland Cancer AJCC v7

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Stage IVC Major Salivary Gland Cancer AJCC v7

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Added because the terminology and the registry both attest it: an NCIt neoplasm concept named by 13 acquired study condition(s). It is absent from the NCI treatment-topic directory, which is not an exhaustive cancer inventory.
      source wording
      Source null

      Study evidence for this setting

      13 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT00095628 · Registry condition search · Scope: narrower

      SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00507767 · Registry condition search · Scope: narrower

      Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

      1 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00588770 · Registry condition search · Scope: narrower

      Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

      5 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT00939627 · Registry condition search · Scope: narrower

      Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

      6 outcome links · 2 safety-group records · 1 quality-of-life measures

      →

      NCT01175980 · Registry condition search · Scope: narrower

      Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT01256385 · Registry condition search · Scope: narrower

      Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy

      6 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT01604772 · Registry condition search · Scope: narrower

      Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma

      4 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT01613768 · Registry condition search · Scope: narrower

      Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer

      5 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT01806675 · Registry condition search · Scope: narrower

      18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

      5 outcome links · 3 safety-group records · 1 quality-of-life measures

      →

      NCT01816984 · Registry condition search · Scope: narrower

      PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT02123511 · Registry condition search · Scope: narrower

      Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

      6 outcome links · 2 safety-group records · 3 quality-of-life measures

      →

      NCT02538510 · Registry condition search · Scope: narrower

      Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

      4 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT03146650 · Registry condition search · Scope: narrower

      Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
      1. release id
        clinical-indications-draft-1
        disease state id
        ds-stage-ivc-major-salivary-gland-cancer-ajcc-v7
        binding id
        ncit-C35696
        source collection
        ncit-concept
        source key
        C35696
        source excerpt
        Source null
        match status
        exact
        match note
        Source null
        recorded at
        2026-09-10T00:00:00Z
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice